Dmitry Balyasny’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Dmitry Balyasny’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-42,000	Closed	-$2.41M	–	1847
2018 Q3	$2.41M	Buy	+42,000	New	+$2.34M	0.01%	924

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Dmitry Balyasny's MRTX Position: Q1 2024 in Review

Dmitry Balyasny sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 19,921 shares — an estimated $1.17M sold.

Dmitry Balyasny first reported a position in MRTX in Q1 2015 and held it in 12 quarters. The position peaked at $33.8M in Q3 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Dmitry Balyasny reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Dmitry Balyasny sold 19,921 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.17M.
Dmitry Balyasny first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2015 and held it in 12 quarters.
Dmitry Balyasny's Mirati Therapeutics, Inc. Common Stock position peaked at $33.8M in Q3 2023.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Balyasny Asset Management's 13F filing for Q1 2024, filed 13 May 2024.